1035 CAMBRIDGE STREET, CAMBRIDGE, MA
Board Appointment - Robert J. Spiegel Joins Ernexa Therapeutics Board
Investor Presentation
Ernexa Therapeutics Inc. Elects Directors at 2026 Annual Meeting
Annual Report to Security Holders
Ernexa Therapeutics Inc. Implements 1-for-25 Reverse Stock Split
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Q2
Q1
FY 2025
Q3
FY 2024
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Certificate
Amended Registration Statement for Securities
Registration of Securities
Definitive Proxy Statement
Additional Proxy Materials
Definitive Information Statement
Preliminary Information Statement
PRE 14A
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence